Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, carglumic acid (Carbaglu®) cannot be endorsed for use within NHS Wales for the treatment of hyperammonaemia due to isovaleric acidaemia; hyperammonaemia due to methymalonic acidaemia; and hyperammonaemia due to propionic acidaemia. |
||
|
||
Medicine details |
||
| Medicine name | carglumic acid (Carbaglu®) | |
| Formulation | 200 mg dispersible tablet | |
| Reference number | 2371 | |
| Indication | Treatment of hyperammonaemia due to isovaleric acidaemia; hyperammonaemia due to methymalonic acidaemia; and hyperammonaemia due to propionic acidaemia |
|
| Company | Orphan Europe (UK) Ltd | |
| BNF chapter | Nutrition & blood | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 06/12/2013 | |